Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both ...

Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and ...

The challenge of maintaining the earlier growth achieved by US mRNA medicines specialist Moderna through its COVID vaccine ...

The heart failure market is projected to grow from $13.5 billion in 2022 to $33.7 billion by 2032, driven by new therapies, ...

City Therapeutics appoints Andrew Orth as CEO, leveraging his expertise in RNA and gene therapies as the company advances its ...

Swiss pharma giant Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 ...

I-Mab shifts focus to givastomig, a bispecific antibody for CLDN18.2-positive tumors, following positive early data and ...

Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space. How has ...

Denali Therapeutics' DNL343 fails to meet endpoints in the HEALEY ALS study, marking a second clinical setback for the ...

The US Food and Drug Administration (FDA) issued a draft guidance to provide recommendations on the use of artificial ...

Administration (FDA) approved an update to the US Prescribing Information (USPI) for Pyrukynd (mitapivat) for the treatment ...

Sentynl Therapeutics secures FDA priority review for CUTX-101, a potential first treatment for Menkes disease. Supported by ...